MA42569B1 - Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent - Google Patents

Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Info

Publication number
MA42569B1
MA42569B1 MA42569A MA42569A MA42569B1 MA 42569 B1 MA42569 B1 MA 42569B1 MA 42569 A MA42569 A MA 42569A MA 42569 A MA42569 A MA 42569A MA 42569 B1 MA42569 B1 MA 42569B1
Authority
MA
Morocco
Prior art keywords
polynucleotide
salt
composition
methods
multivalent cation
Prior art date
Application number
MA42569A
Other languages
English (en)
Inventor
Premchandran Ramiya
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA42569B1 publication Critical patent/MA42569B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des aspects de la description comprennent des procédés pour la préparation d'un polynucléotide. Dans certains modes de réalisation, le procédé comprend la mise en contact d'une première composition polynucléotidique comprenant: un polynucléotide ayant une séquence de 7 sous-unités nucléosidiques ou plus et au moins deux des sous-unités nucléosidiques sont jointes par une liaison inter-sous-unité thiophosphoramidate n3 '? P5'; et des produits synthétiques non ciblés et des réactifs; avec un sel de cation multivalent pour précipiter un sel de polynucléotide comprenant au moins un contre-ion de cation multivalent; et séparer le sel polynucléotidique de la première composition polynucléotidique mise en contact pour produire une seconde composition polynucléotidique comprenant le sel polynucléotidique. Dans certains modes de réalisation, le procédé comprend en outre la mise en contact du sel de polynucléotide avec un support de chromatographie en phase inverse; et en éluant à partir du support de chromatographie une troisième composition polynucléotidique comprenant le polynucléotide. L'invention concerne également des compositions comprenant un sel du polynucléotide comprenant au moins un contre-ion de cation multivalent.
MA42569A 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent MA42569B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562151891P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
MA42569B1 true MA42569B1 (fr) 2020-08-31

Family

ID=55911083

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42569A MA42569B1 (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
MA042157A MA42157A (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA042157A MA42157A (fr) 2015-04-23 2016-04-21 Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent

Country Status (36)

Country Link
US (2) US10745687B2 (fr)
EP (1) EP3286203B1 (fr)
JP (4) JP2018513127A (fr)
KR (1) KR102401252B1 (fr)
CN (2) CN113564168B (fr)
AU (2) AU2016250576C1 (fr)
BR (1) BR112017019627B1 (fr)
CA (1) CA2978191C (fr)
CL (1) CL2017002314A1 (fr)
CO (1) CO2017009217A2 (fr)
CY (1) CY1123197T1 (fr)
DK (1) DK3286203T3 (fr)
EA (1) EA035885B1 (fr)
ES (1) ES2798270T3 (fr)
HR (1) HRP20201218T1 (fr)
HU (1) HUE051148T2 (fr)
IL (1) IL254222A0 (fr)
LT (1) LT3286203T (fr)
MA (2) MA42569B1 (fr)
MD (1) MD3286203T2 (fr)
ME (1) ME03811B (fr)
MX (1) MX383293B (fr)
MY (1) MY187804A (fr)
PE (2) PE20221275A1 (fr)
PH (1) PH12017501927B1 (fr)
PT (1) PT3286203T (fr)
RS (1) RS60645B1 (fr)
SA (1) SA517390103B1 (fr)
SG (2) SG10201909816PA (fr)
SI (1) SI3286203T1 (fr)
SM (1) SMT202000389T1 (fr)
TN (1) TN2017000411A1 (fr)
TW (1) TWI736532B (fr)
UA (1) UA124521C2 (fr)
WO (1) WO2016172346A1 (fr)
ZA (1) ZA201706041B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113564168B (zh) 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
CN108430456B (zh) 2015-10-22 2022-01-18 摩登纳特斯有限公司 癌症疫苗
EP3555289A1 (fr) 2016-12-13 2019-10-23 ModernaTX, Inc. Purification par affinité d'arn
CN110121364A (zh) 2016-12-19 2019-08-13 文塔纳医疗系统公司 肽核酸缀合物
WO2019036683A1 (fr) * 2017-08-18 2019-02-21 Modernatx, Inc. Procédés analytiques par hplc
CN111542606A (zh) * 2017-09-22 2020-08-14 科罗拉多州立大学董事会法人团体 硫吗啉代寡核苷酸用于治疗肌肉营养不良
WO2019120635A1 (fr) 2017-12-18 2019-06-27 Ventana Medical Systems, Inc. Conjugués à base d'acide nucléique peptidique

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE69133235T2 (de) 1990-08-31 2003-11-20 The Regents Of The University Of Minnesota, Minneapolis Verfahren zur Herstellung von Harzen für die Feststoff-Peptidsynthese
US5281701A (en) 1991-07-12 1994-01-25 Applied Biosystems, Inc. Process and compounds for RNA synthesis
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
EP0754242A4 (fr) 1994-03-18 1997-06-11 Lynx Therapeutics Inc SYNTHESE, COMPOSES, HYBRIDATION ET PROPRIETES DE RESISTANCE AUX NUCLEASES D'OLIGONUCLEOTIDES AYANT DES LIAISONS N3'-m(7)P5' PHOSPHORAMIDATES
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
US6114519A (en) 1997-10-15 2000-09-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized oligonucleotides
US6465628B1 (en) 1999-02-04 2002-10-15 Isis Pharmaceuticals, Inc. Process for the synthesis of oligomeric compounds
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2002060341A (ja) 2000-08-21 2002-02-26 Terumo Corp 止血剤
EP1379689B1 (fr) 2001-03-23 2012-09-26 Geron Corporation Conjugues d'oligonucleotide
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
SI3342425T1 (sl) * 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
TW200540180A (en) 2004-05-28 2005-12-16 Sankyo Co Telomerase inhibitor ena oligonucleotide
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
WO2007041201A2 (fr) * 2005-10-03 2007-04-12 Applera Corporation Compositions, procedes et kits pour l'amplification d'acides nucleiques
US9109015B2 (en) 2006-11-01 2015-08-18 Biogen Ma Inc Method of isolating biomacromolecules using low pH and divalent cations
KR20150039873A (ko) * 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
AR091065A1 (es) 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
KR20210072137A (ko) * 2012-06-14 2021-06-16 라이프 테크놀로지스 코포레이션 폴리머라제 연쇄 반응 (pcr)을 위한 신규 조성물, 방법 및 키트
IL280144B2 (en) * 2012-12-07 2025-05-01 Geron Corp Use of telomerase inhibitors to treat bone marrow culture disorders and bone marrow culture tumors
JOP20200257A1 (ar) * 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
CN113564168B (zh) 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法

Also Published As

Publication number Publication date
CO2017009217A2 (es) 2018-02-20
UA124521C2 (uk) 2021-10-05
JP2018513127A (ja) 2018-05-24
BR112017019627B1 (pt) 2022-11-29
TW201706284A (zh) 2017-02-16
SI3286203T1 (sl) 2020-10-30
MA42157A (fr) 2018-02-28
CL2017002314A1 (es) 2018-05-04
CN107429247A (zh) 2017-12-01
JP2021152079A (ja) 2021-09-30
TN2017000411A1 (en) 2019-01-16
NZ735042A (en) 2021-11-26
SA517390103B1 (ar) 2021-07-14
WO2016172346A1 (fr) 2016-10-27
ME03811B (fr) 2021-04-20
BR112017019627A2 (pt) 2018-05-15
AU2016250576C1 (en) 2021-05-06
CA2978191A1 (fr) 2016-10-27
CN113564168A (zh) 2021-10-29
AU2016250576B2 (en) 2021-02-04
MX383293B (es) 2025-03-13
HRP20201218T1 (hr) 2020-12-11
CN113564168B (zh) 2024-10-25
AU2021202803A1 (en) 2021-06-03
US10745687B2 (en) 2020-08-18
IL254222A0 (en) 2017-10-31
CA2978191C (fr) 2022-10-04
PH12017501927A1 (en) 2018-03-05
EP3286203B1 (fr) 2020-05-06
MX2017011642A (es) 2017-11-02
LT3286203T (lt) 2020-07-27
PE20171785A1 (es) 2017-12-27
EA035885B1 (ru) 2020-08-27
HUE051148T2 (hu) 2021-03-01
JP2022168017A (ja) 2022-11-04
ES2798270T3 (es) 2020-12-10
PH12017501927B1 (en) 2022-09-02
TWI736532B (zh) 2021-08-21
AU2016250576A1 (en) 2017-09-21
PE20221275A1 (es) 2022-09-01
MD3286203T2 (ro) 2020-08-31
SG10201909816PA (en) 2019-11-28
SMT202000389T1 (it) 2020-09-10
CY1123197T1 (el) 2021-10-29
SG11201707893RA (en) 2017-11-29
KR102401252B1 (ko) 2022-05-24
PT3286203T (pt) 2020-07-08
US20200339975A1 (en) 2020-10-29
JP2025061848A (ja) 2025-04-11
HK1251234A1 (en) 2019-01-25
DK3286203T3 (da) 2020-06-02
KR20170138399A (ko) 2017-12-15
US11441144B2 (en) 2022-09-13
EP3286203A1 (fr) 2018-02-28
CN107429247B (zh) 2021-08-13
EA201791753A1 (ru) 2018-04-30
ZA201706041B (en) 2020-11-25
US20160312227A1 (en) 2016-10-27
MY187804A (en) 2021-10-26
RS60645B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
MA42157A (fr) Procédés de préparation de polynucléotides à l'aide de compositions de sel cationique multivalent
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
MA40801B2 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
WO2018064589A9 (fr) Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante
EA201890565A1 (ru) Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
WO2017123673A3 (fr) Protéines de fusion multivalentes et multispécifiques fixant ox40
WO2017015623A3 (fr) Protéines hybrides multivalentes et multispécifiques se liant à gitr
MA40882A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
WO2015184349A3 (fr) Composés liant ras multivalents
WO2013115926A3 (fr) Conjugués aspartyl-arnt synthétase-fc
MA40481A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante
WO2010062779A3 (fr) Adn polymérases modifiées
FR2964618B1 (fr) Dispositif de solidarisation d'une lampe sur un balai d'essuyage
EA201890082A1 (ru) Эпитоп антитела
WO2017011837A3 (fr) Protéines de fusion se liant à dr5 multivalentes et multispécifiques
LT3663401T (lt) Biologinių molekulių, tokių kaip plazmidinė dnr, gryninimo būdas, panaudojant anijonų mainų chromatografiją
MA40793A1 (fr) Composition acide a base de leonardite et d'acides amines
FR3016888B1 (fr) Synthetases de la colistine et cluster de genes correspondants
MA40371A (fr) Sélectivité efficace des protéines recombinées
MX2021016092A (es) Metodos de purificacion de proteinas.
MA47671B1 (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf